A 9-point risk assessment identified persons with a history of injection drug use who were safe for discharge. "Low-risk" patients were discharged with outpatient antibiotics; others continued inpatient treatment. Use of the assessment reduced the mean length of stay by 20 days and total direct cost by 33%, creating capacity for an additional 333 patients.
Acute infections, including bloodstream infections, infective endocarditis (IE), skin and soft-tissue infections (SSTIs) are common among persons who inject drugs (PWID) and are associated with hospital length of stay (LOS), readmissions, and skyrocketing healthcare costs [1, 2] . At the University of Alabama at Birmingham (UAB) Hospital between 2015 and 2016, the annual number of IE cases increased by 56% (from 142 to 222 cases) resulting in a 27% increase in patient-days (from 2973 to 3788 patient-days). Direct costs related to IE rose from $4.8 to $5.5 million (J. DeMoss, personal communication, 26 July 2018). Understanding the resources needed for optimal management of acute infections is essential to develop policy and best care practices for PWID.
There are limited, conflicting data [3, 4] as to whether and when outpatient care is appropriate for PWID needing prolonged intravenous antibiotics, owing to concerns that PWID may use their central access to inject opioids and that home health agencies and/or pharmacies are unwilling to provide intravenous antibiotics to PWID, and due to lack of resources (insurance, housing, and/or social support) [5] .
Hospitalization of PWID presents opportunities to address both addiction and infection. We implemented an Intravenous Antibiotics and Addiction Team (IVAT) for multidisciplinary care of PWID in 2016. In a prior assessment of the 14 months before and 5 months after it, the IVAT intervention reduced mean LOS (MLOS) (42 vs 18.5 days; P = .001) without increasing the number of readmissions within 30 days (7 vs 6 readmissions; P = .27) [6] . In the current study, we analyzed the cost of care for PWID before and after the IVAT intervention from the perspective of the health system.
METHODS

Intervention
The UAB Hospital, a 1157-bed tertiary care center, implemented the IVAT intervention with the goal of risk stratifying PWID, regardless of their drug of abuse (eg, opiates or amphetamines), according to their risk of ongoing intravenous drug use (IVDU) while receiving intravenous antibiotics. Persons receive IVAT consultation if they meet the following criteria: hospital admission, history of IVDU, and indication for prolonged intravenous antibiotics (eg, bloodstream infections, IE, SSTIs, and bone and joint infections). As reported elsewhere [6] , faculty developed a 9-point risk assessment (Supplementary Table 1 ) that queries the following: cravings, home environment, dual psychiatric diagnoses, history of overdose, relapse, trauma, use of multiple drugs, family history of addiction, and willingness to change. Results allow addiction medicine consultants to make recommendations for addiction support and pharmacotherapy needs. "Low-risk" patients (1-3 points) are discharged for the duration of antibiotics and participation in outpatient addiction care. "Medium-risk" and "high-risk" patients (4-6 and 7-9 points, respectively) are kept as inpatients and offered group therapy, opioid agonist therapy (if applicable), and assessment for discharge readiness [6] . Because the IVAT risk assessment is a low-technology tool that is incorporated into the workflow for addiction medicine consultants, it does not require additional resources, and no additional charges are accrued. In this economic assessment, we extended the data collection period to 14 months after IVAT implementation to increase the sample size and added inpatient direct costs.
Economic Assessment
In the pre-IVAT period (January 2015 to February 2016), we retrospectively analyzed the UAB inpatient electronic database for inpatient encounters at the UAB Hospital in which intravenous antibiotics were received for ≥14 days. Patients were included in the pre-IVAT period if they disclosed or had a documented history of IVDU in record review. In the post-IVAT period (October 2016 to January 2018), patients were included if they were referred for IVAT consultation based on clinical suspicion for IVDU. Admissions from February 2016 to October 2016 were excluded because this period was used to implement the IVAT. To quantify costs in a real-world setting, we did not exclude subsequent admissions by the same patient if the admission otherwise met inclusion criteria. Costs were defined as direct costs per encounter obtained by querying financial accounts. Outpatient costs were not available and thus were excluded.
Subanalysis
We evaluated the cost and LOS according to the primary bacterial infection diagnosed and requiring intravenous antibiotics. For patients with multiple admissions during the study period, we analyzed only the first admission. This study was approved by the UAB Institutional Review Board.
RESULTS
A total of 37 discrete patients had 37 admissions meeting inclusion criteria in the pre-IVAT period. A total of 100 patients accounted for 111 admissions meeting criteria in the post-IVAT period. The MLOS was 42 days for the pre-IVAT and 22 days for the post-IVAT period. Differences between the pre-and post-IVAT cohorts are shown in Table 1 .
Direct costs per admission in the post-IVAT period were 33% lower than in the pre-IVAT period: $26 014 versus $38 716 ( Table 1) . Twenty-five patients (27%) in the post-IVAT period were low risk. Costs were $922 per day per admission and $1182 per day per admission in the pre-and post-IVAT periods, respectively. Overall inpatient costs per day were greater in the post-IVAT period.
The MLOS at UAB is 6.58 days (J. Russell, personal communication, 3 April 2018). A 20-day reduction in MLOS in the post-IVAT period translates to a mean of 3 additional inpatient encounters (20/6.58). This translates to a net gain of 333 (3 × 111) additional inpatient encounters in the post-IVAT period; the reduced MLOS creates capacity for 333 other patients. Alternatively, without the IVAT intervention, the MLOS would remain 20 days longer for the 111 patients receiving care in the postintervention period, resulting in an additional 2220 patient-days.
In the subanalysis, the median cost and LOS according to primary diagnosis declined in the post-IVAT period for all bacterial infections, including IE (Supplementary Table 2 ). The greatest reduction in LOS occurred in patients with bone and joint infections, for whom LOS declined by a median of 38.5 days.
DISCUSSION
The UAB Health System is the largest in the state and provides care for PWID referred from other health systems across the Southeast. Due to rising numbers of PWID with infections requiring prolonged intravenous antibiotics, UAB developed a 9-point risk assessment to identify those safe for discharge with intravenous antibiotics. A prior analysis demonstrated that the IVAT decreases MLOS (42 vs 18.5 days; P = .001) without increasing 30-day readmissions (7 vs 6 readmissions; P = .27) [6] .
In the current study, which added post-IVAT clinical data and cost data, the IVAT intervention reduced costs by 33%, reduced hospital LOS, and created capacity for 333 additional patients. The results are intuitive and reassuring: providing outpatient care for PWID at low risk for continued IVDU reduces LOS and hospital costs. Transitioning these patients safely to outpatient care allows the health systems to prioritize inpatient care for those PWID at great risk for ongoing IVDU, who will require resource-intensive admissions, including intravenous antibiotics. Costs across all services declined with use of the IVAT. Direct costs increased from approximately $922 to $1182 per admission per day. It is not surprising that the shorter LOS in the post-IVAT period is accompanied by an increased cost per day; a greater number of necessary services (ie, echocardiography, peripherally inserted central catheter placement, laboratory tests) typically occur in the initial days of the hospitalization.
The disproportionately large number of PWID included in the post-IVAT study period relative to the pre-IVAT period (each 14 months) demonstrates the rising number of PWID seeking care as a result of the opioid epidemic. It is also plausible that the number of patients in the post-IVAT period is larger because availability of the IVAT has heightened awareness on the part of providers who better identify and refer PWID. The result is that the sample of participants receiving care in the post-IVAT period is different from that in the pre-IVAT era when only patients with the most severe bacterial infections (ie, IE, epidural abscess) were identified as PWID. After implementation of the IVAT, there has been a greater proportion of less acute infections, including osteomyelitis and SSTI, and a smaller proportion of IE cases. Differences in the pre-and post-IVAT populations reflect these changes in sampling with the IVAT, which has increased recognition of IVDU in less traditional patients: older and with less severe infections. However, it is noteworthy that absolute numbers of all infections, including IE, increased with the IVAT intervention. The percentage of uninsured PWID decreased and commercial insurance increased, consistent with national trends [7] .
The current findings may not be generalizable to other health systems because our study analyzed a single academic health system. However, we believe others may benefit from this multidisciplinary approach to PWID. Because PWID may be polysubstance abusers, it is unclear whether IVAT outcomes vary by drug of abuse (eg, opiates vs amphetamines). We have relied on direct costs as a surrogate for use of resources. We do not have access to outpatient costs, which would contribute to overall resource use for the care of PWID. It is possible that changes in the acuity of infections contributed to the reduced LOS and costs. However, the fact that costs and LOS decreased across all infections, including endocarditis, argues against this.
A 9-point risk assessment for PWID requiring intravenous antibiotics may allow health systems to focus resources on those at greatest risk of ongoing IVDU without compromising the care of others. A reduction in MLOS reduces costs while creating additional capacity. With the IVAT, health systems may reallocate resources to help PWID transition safely to outpatient care (eg, social support, naloxone, medication-assisted treatment).
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